Current Report Filing (8-k)
June 29 2023 - 4:32PM
Edgar (US Regulatory)
0001279704
false
0001279704
2023-06-28
2023-06-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 28, 2023
Cellectar
Biosciences, Inc.
(Exact name of Registrant as Specified in its
Charter)
Delaware | |
1-36598 | |
04-3321804 |
(State or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(IRS Employer
Identification No.) |
100
Campus Drive, Florham Park, NJ, 07932
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including
area code: (608) 441-8120
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
Stock, par value $0.00001 per share |
|
CLRB |
|
The
Nasdaq
Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
On June 28, 2023, the Company announced data from its ongoing study
of iopofosine I 131 in multiple myeloma as presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
The data included that from 72 patients, of which 64 were evaluable, with relapsed or refractory multiple myeloma (MM), in which iopofosine
I 131 demonstrated an overall response rate (ORR) of 23%, a clinical benefit rate (CBR) of 70% and a disease control rate (DCR) of 92%.
The data highlighted the outcomes from two dose levels (<60 mCi vs. >60 mCi total administered dose) across these highly refractory
patients. The focus of the Company’s presentation at SNMMI was on 28 patients that received the optimal dose of >60 mCi total
administered dose (TAD). These patients were predominately either post-BCMA immunotherapy, triple-class refractory (defined as refractory
to immunomodulatory agents, proteasome inhibitors and CD 38 targeted monoclonal antibodies) or quad-class refractory (defined as triple-class
plus refractory to either nuclear export inhibitors or BCMA targeted therapies).
Key data in the patients receiving >60 mCi TAD included:
| • | Overall response rate (ORR) of 32%, |
| • | Clinical benefit rate (CBR) of 75% |
| • | Disease control rate (DCR) of 85.7%. |
Key data in patient subsets that were highly refractory and received
>60 mCi TAD included:
| • | 46% ORR in triple-class refractory patients, median PFS of 3.4
months (n=18) |
| • | 50% ORR in quad-class refractory patients, PFS evaluation ongoing
(n=6) |
| • | 50% ORR in post BCMA relapsed or refractory patients, median
PFS of 3.3 months (n=6) |
The most commonly observed treatment emergent adverse events were consistent
with those previously reported: cytopenias including Grade 3 or 4 thrombocytopenia (62.5%), anemia (62.5%), neutropenia (62.5%), and decreased
white blood cell count (50%). Importantly, patients did not experience off-target treatment emergent adverse events of neuropathy, arrythmia,
cardiovascular events, bleeding, ocular toxicities, changes in renal function, alterations in liver enzymes, or infusion-site reactions.
Patients in the trial received up to four (4), approximately 15-minute
IV infusions of iopofosine over three (3) months, with doses given 14 days apart in each cycle with a maximum of two (2) cycles. Low-dose
dexamethasone 40 mg weekly (20mg in patients ≥ 75), was provided for up to 12 weeks.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
Number |
|
Title |
104 |
|
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELLECTAR BIOSCIENCES, INC. |
|
|
|
Date: June 29, 2023 |
By: |
/s/ Chad J. Kolean |
|
Name: |
Chad J. Kolean |
|
Title: |
Chief Financial Officer |
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024